# A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment

> **NCT05516979** · PHASE2 · COMPLETED · sponsor: **SynAct Pharma Aps** · enrollment: 127 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** 100 mg AP1189
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05516979
- **Lead sponsor:** SynAct Pharma Aps
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-26
- **Primary completion:** 2023-07-20
- **Final completion:** 2023-07-20
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05516979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05516979, "A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05516979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*